Several human papillomavirus (HPV) vaccines, including Cervarix and Gardasil, have been approved to protect against infections with particular types of HPV, associated with cervical and other cancers. All vaccines protect against the high-risk HPV types 16 and 18. Gardasil is a quadrivalent vaccine that additionally protects against low-risk HPV-6 and -11, which are associated with most cases of genital warts. A second-generation nine-valent Gardasil vaccine protects against five additional high-risk HPV types. It is estimated that the vaccines may prevent 70% of cervical cancer, 80% of anal cancer, 60% of vaginal cancer, 40% of vulvar cancer and possibly some oropharyngeal cancers. Protection lasts for at least 8–9 years. Some advocate giving Gardasil to men and boys with the primary aim of protecting their female sexual partners; others consider vaccinating only women and girls to be more cost effective. The licensed vaccines are subunit vaccines, containing only the L1 capsid protein of the virus, which self-assembles into virus-like particles. They are not effective in people already infected with HPV. Research is ongoing into therapeutic HPV vaccines including the viral oncoproteins, E6 and E7, but none has yet been licensed.